Diurnal, a drug developer spun out of Sheffield University, plans to raise up to £6m ($10.11m) to bring its drug Chronocort to market.
Diurnal is a portfolio company of IP Group, who has already committed £4.1m ($6.92m). If fully invested, this would give IP Group a majority stake of 51.7% in the company.
Chronocort is used to treat Congenital Adrenal Hyperplasia, a genetic condition which results in the swelling of adrenal glands. These glands can be found at the top…
University venture funds are becoming an increasingly important tool for universities to support their ecosystems — here are the new ones launched in 2024.
Global University Venturing (GUV) is where tech transfer, academic and investment experts meet to explore the latest ideas and technologies driving innovation forward. We drive the discussions and share best practices that are critical to the success of spinouts, scaleouts and innovation programmes. Our aim is to help improve the processes of bringing innovations from academia to global markets and facilitate their integration into the broader business ecosystem.
